| Patient | Sun Yat-sen |
|---|---|
| Date of birth | 1866-11-12 |
| Identifiers | MRN HR-ET016-SYN-TD; SSN (made up) 000-16-4183 |
| Document date | 1924-10-26 |
| Author | Wen-Li Huang, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Before cycle 8: restaging CT, side effects, low magnesium, and the plan for maintenance. [S]
Mr. Sun returns before his eighth and last cycle of chemotherapy, five weeks after his preventive visit. Cycles 4 to 7 were given on schedule; the cold he had during cycle 5 settled without fever. For two weeks he has had a light tingling in his fingertips that does not affect buttoning or writing. He has had muscle cramps in his calves at night. He has no diarrhea, rash, cough or breathlessness, and no hearing change. His weight is steady. The ache under his ribs has gone most days. His HIV test from the preventive visit was negative. The restaging CT and HBV DNA four days ago are back. [S]
| Element | Detail |
|---|---|
| Cycles | Seven, on schedule |
| New symptoms | Fingertip tingling for two weeks; night cramps in the calves |
| Immune-related symptoms | None |
| Weight | Steady |
| Results | HIV test negative; restaging CT and HBV DNA back |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired after infusions; weight 59.6 kg; no fever |
| Musculoskeletal | Positive | Night cramps in both calves |
| Neurological | Positive | Light tingling in the fingertips; no weakness; buttons and writes normally |
| Ears, nose, mouth, and throat | Negative | No tinnitus or hearing change |
| Gastrointestinal | Negative | Ache mostly gone; nausea mild after infusions; no diarrhea |
| Respiratory | Negative | No cough or breathlessness |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a day | Two tablets by mouth every 8 hours as needed, no more than 3,000 mg a day | Oral route | 1924-05-04 | active | S |
| Gemcitabine 1,000 mg/m2 (1,660 mg) intravenous infusion on days 1 and 8 of each 21-day cycle | Days 1 and 8 of each 21-day cycle, up to 8 cycles | Intravenous route | 1924-06-01 | active | S |
| Cisplatin 25 mg/m2 (41 mg) intravenous infusion on days 1 and 8 of each 21-day cycle | Days 1 and 8 of each 21-day cycle, up to 8 cycles, with hydration | Intravenous route | 1924-06-01 | active | S |
| Durvalumab 1,500 mg intravenous infusion on day 1 of each 21-day cycle | Day 1 of each 21-day cycle with chemotherapy, then every 4 weeks alone | Intravenous route | 1924-06-01 | active | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet by mouth every 8 hours as needed for nausea | Oral route | 1924-06-01 | active | S |
| Magnesium oxide 400 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1924-10-26 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1924-10-26 | Body height | 165 | cm | S |
| 1924-10-26 | Body weight | 59.6 | kg | S |
| 1924-10-26 | Body mass index (BMI) [Ratio] | 21.9 | kg/m2 | S |
| 1924-10-26 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1924-10-26 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1924-10-26 | Heart rate | 80 | /min | S |
| 1924-10-26 | Respiratory rate | 16 | /min | S |
| 1924-10-26 | Body temperature | 36.6 | Cel | S |
| 1924-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1924-10-26 | Leukocytes [#/volume] in Blood by Automated count | 4.3 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1924-10-26 | Neutrophils [#/volume] in Blood by Automated count | 2.1 | 10*3/uL | 1.8-7.7 10*3/uL | Normal | S |
| 1924-10-26 | Hemoglobin [Mass/volume] in Blood | 10.7 | g/dL | 13.2-17.1 g/dL | Low | S |
| 1924-10-26 | Platelets [#/volume] in Blood by Automated count | 176 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1924-10-26 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 1924-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1924-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.95 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1924-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1919)/1.73 sq M | 93 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1924-10-26 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 1924-10-26 | Magnesium [Mass/volume] in Serum or Plasma | 1.6 | mg/dL | 1.7-2.2 mg/dL | Low | S |
| 1924-10-26 | Albumin [Mass/volume] in Serum or Plasma | 3.7 | g/dL | 3.5-5 g/dL | Normal | S |
| 1924-10-26 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.2-1.2 mg/dL | Normal | S |
| 1924-10-26 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 141 | U/L | 40-129 U/L | High | S |
| 1924-10-26 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 10-40 U/L | Normal | S |
| 1924-10-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-55 U/L | Normal | S |
| 1924-10-26 | Thyrotropin [Units/volume] in Serum or Plasma | 3.1 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 1924-10-26 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 121 | U/mL | <=35 U/mL | High | S |
| 1924-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 1924-10-26 | ECOG Performance Status score | 1 | {score} | S |
Vital signs recorded on 1924-10-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin, well; blood pressure 124/78, pulse 80; weight 59.6 kg; no jaundice |
| Abdomen | Liver edge 2 cm below the right costal margin; no ascites |
| Neurological | Vibration slightly reduced at the fingertips; light touch, strength and reflexes normal |
| Skin | No rash; port site clean |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Right upper quadrant abdominal mass with weight loss: a dull ache under the right ribs and early fullness for about three months, 4 kg weight loss, and a firm, non-tender mass felt 4 cm below the right costal margin; no jaundice, fever, or itching. Ultrasound today: a 6.8 cm solid, heterogeneous mass in liver segments IV and V that cannot be separated from the gallbladder, which contains stones; the rest of the liver is smooth, with no ascites. Multiphase CT, tumor markers, hepatitis serology and medical oncology consultation arranged | resolved | confirmed | R19.01 | S — Synthetic presenting problem anchored to the documented right upper abdominal mass; superseded by the biopsy diagnosis. |
| Adenocarcinoma of the gallbladder invading the liver: core biopsy of the liver mass shows moderately differentiated adenocarcinoma (CK7 positive, CK20 and CDX2 negative), and multiphase CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged nodes in the hepatoduodenal ligament; no cirrhosis; alpha-fetoprotein normal, CA 19-9 raised. Clinical T3 N1 before staging laparoscopy (AJCC 8th edition). Synthetic modern episode linked to his documented final illness, described in life as liver cancer and at autopsy as gallbladder adenocarcinoma | active | confirmed | C23 | S — Synthetic modern diagnosis chosen to fit the documented findings: a mass involving the liver at operation and gallbladder adenocarcinoma at autopsy. |
| Resolved hepatitis B infection: hepatitis B surface antigen negative, total core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative. At risk of reactivation during chemotherapy and immunotherapy; monitored | active | confirmed | Z86.19 | S — Synthetic serology; not a claim that he had hepatitis B in his lifetime. No fetched source mentions hepatitis. |
| Peritoneal metastases from gallbladder adenocarcinoma: several 3 to 6 mm nodules on the parietal peritoneum and omentum at staging laparoscopy, biopsy positive for adenocarcinoma of the same type; stage IVB (M1), not resectable | active | confirmed | C78.6 | S — Synthetic finding anchored to the peritoneal metastases reported at autopsy. |
| Acute viral upper respiratory infection on day 10 of cycle 5 of chemoimmunotherapy: sore throat, runny nose and dry cough for three days, afebrile, with a neutrophil count of 1.6 x10^3/uL; rapid tests for SARS-CoV-2 and influenza negative; no sign of pneumonia or pneumonitis; resolved | resolved | confirmed | J06.9 | S — Synthetic acute illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | CT of the chest, abdomen and pelvis | At staging, then every 2 to 3 months on treatment | Completed today | Four days ago: mass 4.9 cm; partial response, sum down 33% from baseline; no new lesions |
| Laboratory | CA 19-9 (and CEA when raised) | At diagnosis, then with each cycle or restaging | Completed today | CA 19-9 121 U/mL |
| Laboratory | Blood count with neutrophils | Before every dose (days 1 and 8) | Completed today | White cells 4.3, neutrophils 2.1, hemoglobin 10.7 g/dL, platelets 176 |
| Laboratory | Creatinine and eGFR | Before every dose (days 1 and 8) | Completed today | Creatinine 0.95 mg/dL, eGFR 93 |
| Laboratory | Magnesium and potassium | Before every dose (days 1 and 8) | Completed today | Magnesium 1.6 mg/dL (low), potassium 4.1 mmol/L, sodium 137 mmol/L; magnesium oxide started |
| Laboratory | Liver tests (bilirubin, alkaline phosphatase, AST, ALT, albumin) | Before every dose (days 1 and 8) | Completed today | Bilirubin 0.6 mg/dL, alkaline phosphatase 141, AST 31, ALT 28 U/L, albumin 3.7 g/dL |
| Laboratory | TSH | Baseline, then every 4 to 6 weeks on durvalumab | Completed today | 3.1 mIU/L |
| Laboratory | Glucose | Baseline, then with each pre-dose chemistry panel on durvalumab | Completed today | 96 mg/dL |
| Laboratory | HBV DNA and ALT (resolved hepatitis B) | Every 3 months during treatment and for 6 to 12 months after | Completed today | HBV DNA undetectable four days ago; ALT 28 U/L |
| Medication safety | Immune-related side effects (diarrhea, rash, cough or breathlessness, fatigue, endocrine symptoms) | Every visit | Completed today | None |
| Medication safety | Chemotherapy side effects: nausea, fatigue, neuropathy, hearing | Every visit | Completed today | Grade 1 sensory neuropathy; night cramps with low magnesium |
| Examination | Hearing (cisplatin) | Baseline before cisplatin, then by symptoms each cycle | Completed today | No hearing symptoms; the audiogram is not needed unless symptoms appear |
| Survey | ECOG performance status | Every visit | Completed today | ECOG 1 |
| Examination | Weight and nutrition | Every visit | Completed today | 59.6 kg, within 0.4 kg of the start of treatment |
| Survey | Pain | Every visit | Completed today | 0 to 1 of 10 |
| Survey | Distress and depression (PHQ-9) | At each change in treatment or status | Completed today | PHQ-9 4 |
| Referral | Specialist palliative care | From the diagnosis of advanced cancer | Completed today | Seen every 3 to 4 weeks |
| Self-management | Goals of care and advance care planning | At diagnosis and at each change in treatment | Completed today | Goals reviewed with the move to maintenance; agent named at the preventive visit |
| Self-management | Vaccination review | Yearly and during treatment | Completed today | Influenza, COVID-19 and PCV20 at the preventive visit; first recombinant zoster dose today |
Goal progress:
Immunizations given today: Recombinant zoster vaccine, first of two doses [S]
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026); Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1) (2022); Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (2020); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021); Adult Immunization Schedule by Medical Condition and Other Indication (2026)
Follow-up: Cycle 8 day 8 next week. Durvalumab maintenance every 4 weeks from four weeks after today. Second zoster dose in one to two months. Restaging CT in 2 to 3 months. [S]